Arca
Skip to content

BLA 761356: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761356's history or Gan & Lee Pharmaceuticals's company page.

On Apr 12, 2024, FDA declined to approve BLA 761356 (BLA 761356) from Gan & Lee Pharmaceuticals in its present form, citing product quality, facility inspections. openFDA lists it as not yet approved.

  • Letter date: Apr 12, 2024
  • Application: BLA 761356
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Product qualityFacility inspections

The Letter

Text from openFDA

Silver Spring, MD 20993 www.fda.gov U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov FACILITY INSPECTIONS 6. Following pre-license inspection 0 a listed in this application, conveyed deficiencies to the representative of the facility. Your...… openFDA did not return the full text just now. Open it in the letter search.

Gan & Lee Pharmaceuticals's Other Letters

Newest first
  • BLA 761357Mar 26, 2024 · BLA 761357 · not approved

Record

Company
Gan & Lee Pharmaceuticals
Application
BLA 761356
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.